BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Freeman MP, Pooley J, Flynn MJ, Baer L, Mischoulon D, Mou D, Fava M. Guarding the Gate: Remote Structured Assessments to Enhance Enrollment Precision in Depression Trials. J Clin Psychopharmacol 2017;37:176-81. [PMID: 28187008 DOI: 10.1097/JCP.0000000000000669] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Dichtel LE, Carpenter LL, Nyer M, Mischoulon D, Kimball A, Deckersbach T, Dougherty DD, Schoenfeld DA, Fisher L, Cusin C, Dording C, Trinh NH, Pedrelli P, Yeung A, Farabaugh A, Papakostas GI, Chang T, Shapero BG, Chen J, Cassano P, Hahn EM, Rao EM, Brady RO Jr, Singh RJ, Tyrka AR, Price LH, Fava M, Miller KK. Low-Dose Testosterone Augmentation for Antidepressant-Resistant Major Depressive Disorder in Women: An 8-Week Randomized Placebo-Controlled Study. Am J Psychiatry 2020;177:965-73. [PMID: 32660299 DOI: 10.1176/appi.ajp.2020.19080844] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
2 Papakostas GI, Johe K, Hand H, Drouillard A, Russo P, Kay G, Kashambwa R, Hoeppner B, Flynn M, Yeung A, Martinson MA, Fava M. A phase 2, double-blind, placebo-controlled study of NSI-189 phosphate, a neurogenic compound, among outpatients with major depressive disorder. Mol Psychiatry 2020;25:1569-79. [PMID: 30626911 DOI: 10.1038/s41380-018-0334-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
3 Feeney A, Hock RS, Fava M, Hernández Ortiz JM, Iovieno N, Papakostas GI. Antidepressants in children and adolescents with major depressive disorder and the influence of placebo response: A meta-analysis. J Affect Disord 2022;305:55-64. [PMID: 35247482 DOI: 10.1016/j.jad.2022.02.074] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Cosci F, Fava GA. Staging of unipolar depression: systematic review and discussion of clinical implications. Psychol Med 2022;:1-8. [PMID: 35655409 DOI: 10.1017/S0033291722001507] [Reference Citation Analysis]
5 Bugarski-Kirola D, Arango C, Fava M, Nasrallah H, Liu IY, Abbs B, Stankovic S. Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe. Lancet Psychiatry 2022;9:46-58. [PMID: 34861170 DOI: 10.1016/S2215-0366(21)00386-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
6 Demyttenaere K, Jaspers L. Trends in (not) using scales in major depression: A categorization and clinical orientation. Eur Psychiatry 2020;63:e91. [PMID: 32962793 DOI: 10.1192/j.eurpsy.2020.87] [Reference Citation Analysis]
7 Butelman ER, Kreek MJ. Medications for substance use disorders (SUD): emerging approaches. Expert Opin Emerg Drugs 2017;22:301-15. [PMID: 29057665 DOI: 10.1080/14728214.2017.1395855] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
8 Brown S, Rittenbach K, Cheung S, McKean G, MacMaster FP, Clement F. Current and Common Definitions of Treatment-Resistant Depression: Findings from a Systematic Review and Qualitative Interviews. Can J Psychiatry 2019;64:380-7. [PMID: 30763119 DOI: 10.1177/0706743719828965] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 14.7] [Reference Citation Analysis]
9 Rette D, McDonald E, Iosifescu DV, Collins KA. Neural Predictors of the Antidepressant Placebo Response. Pharmaceuticals (Basel) 2019;12:E158. [PMID: 31635043 DOI: 10.3390/ph12040158] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]